Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Moxifloxacin ophthalmic solution - Alcon

Drug Profile

Moxifloxacin ophthalmic solution - Alcon

Alternative Names: AL-15469A; BAY-12-8039; BAY-X-8843; Kanavig; Moxafloxacin hydrochloride; Moxeza; Moxifloxacin hydrochloride ophthalmic solution - Alcon; Moxifloxacin hydrochloride otic solution - Alcon; Moxivig; Vegamox; Vigamox; Vigamoxi

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Alcon
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis; Postoperative infections
  • Discontinued Otitis externa

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2014 Alcon completes a phase III trial in infectious conjunctivitis in USA (NCT01573910)
  • 03 May 2012 Alcon initiates enrolment in a phase III trial in Infectious conjunctivitis in USA (NCT01573910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top